For January 2021, we have selected: M. Obermann et al. Safety and efficacy of prednisone versus placebo in short-term prevention of episodic cluster headache: a multicentre, double-blind, randomised controlled trial. Lancet Neurol 2020, November 24, 2020. https://doi.org/10.1016/S1474-4422(20)30363-X.
For December 2020, we have selected the following two papers: Zhang Q et al. ''COVID-19 case fatality and Parkinson’s disease'' and Bsteh G, et al. ''Multiple sclerosis and COVID-19: how many are at risk?''
For November 2020, we have selected: Agarwal P. et al. Neurological manifestations in 404 COVID‑19 patients in Washington State. J Neurol 2020 Aug 6;1-3. doi: 10.1007/s00415-020-10087-z. Online ahead of print.
For November 2020, we have selected: Wang Z. et al. Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease. JAMA Neurol 2020;e203311. doi: 10.1001/jamaneurol.2020.3311. Online ahead of print.
For October 2020, we have selected the following Covid-19 paper: Hernández-Fernández F. et al. Cerebrovascular disease in patients with COVID-19: neuroimaging, histological and clinical description. Brain 2020 Jul 9;awaa239. doi: 10.1093/brain/awaa239. Online ahead of print.
For August 2020, we have selected Turner R.S. et al. “Nilotinib Effects on Safety, Tolerability,and Biomarkers in Alzheimer’s Disease” Annals of Neurology 2020;88:183–194. doi: 10.1002/ana.25775. Epub 2020 May 28.
For August 2020, we have selected Rogers J.P. et al. “Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic” Lancet Psychiatry 2020; 7:611-627.
For May 2020, we have selected: Lechien JR, Chiesa-Estomba CM, De Siati DR et al. Olfactory and gustatory dysfunctions as a clinical presentation of mild‑to‑moderate forms of the coronavirus disease (COVID‑19): a multicenter European study.